Wang, Shasha Lou, Ning Luo, Rongrong Hao, Xuezhi Liu, Yutao Wang, Lin Shi, Yuankai Han, Xiaohong
Published in
Journal of translational medicine
The identification of early plasma biomarkers for clinical outcomes and drug resistance has key importance for risk stratification in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients. Moreover, it remains unclear whether the anti-angiogenic drug anlotinib can reverse the resistance of ALK-tyrosine kinas...
Sriramkumar, Shruthi Sood, Riddhi Huntington, Thomas D Ghobashi, Ahmed H Vuong, Truc T Metcalfe, Tara X Wang, Weini Nephew, Kenneth P O'Hagan, Heather M
Published in
Journal of translational medicine
Platinum based agents-cisplatin and carboplatin in combination with taxanes are used for the treatment of ovarian cancer (OC) patients. However, the majority of OC patients develop recurrent, platinum resistant disease that is uniformly fatal. Platinum treatment enriches for chemoresistant aldehyde dehydrogenase (ALDH) + ovarian cancer stem cells (...
Li, Qihang Zhang, Zhiyu Jiang, HongChao Hou, Jun Chai, Yuhang Nan, Hongxing Li, Feng Wang, Lianghai
Published in
Journal of translational medicine
Emerging evidence has highlighted the critical roles of long noncoding RNAs (lncRNAs) in tumor development and progression. However, the biological functions and underlying mechanisms of DLEU1 in esophageal squamous cell carcinoma (ESCC) remain unclear. LncRNA expression in ESCC tissues was explored using lncRNA microarray datasets. The functional ...
Liu, Hui-Hui Guo, Yuan-Lin Zhu, Cheng-Gang Wu, Na-Qiong Gao, Ying Xu, Rui-Xia Dong, Qian Qian, Jie Dou, Ke-Fei Li, Jian-Jun
...
Published in
Journal of translational medicine
Currently, remnant cholesterol (RC), lipoprotein(a) [Lp(a)], and inflammation are considered the principal residual cardiovascular risk (RCVR) factors. This study sought to evaluate the combined impact of RC, Lp(a), and inflammation on prognosis of statin-treated patients with chronic coronary syndrome (CCS), which has not been investigated. A tota...
Tang, Xinjun Liang, Li Hu, Lijuan Song, Yuanlin
Published in
Journal of translational medicine
Al-Farsi, Halema Al-Azwani, Iman Malek, Joel A Chouchane, Lotfi Rafii, Arash Halabi, Najeeb M
Published in
Journal of translational medicine
Mutated and non-mutated genes interact to drive cancer growth and metastasis. While research has focused on understanding the impact of mutated genes on cancer biology, understanding non-mutated genes that are essential to tumor development could lead to new therapeutic strategies. The recent advent of high-throughput whole genome sequencing being ...
Brown, Christine E. Bucktrout, Samantha Butterfield, Lisa H. Futer, Olga Galanis, Evanthia Hormigo, Adilia Lim, Michael Okada, Hideho Prins, Robert Marr, Sara Siebel
...
Published in
Journal of Translational Medicine
Harnessing the effector mechanisms of the immune system to combat brain tumors with antigen specificity and memory has been in research and clinical testing for many years. Government grant mechanisms and non-profit organizations have supported many innovative projects and trials while biotech companies have invested in the development of needed to...
Kouro, Taku Himuro, Hidetomo Sasada, Tetsuro
Published in
Journal of Translational Medicine
Chimeric antigen receptor (CAR) T cell therapy has attracted attention for its promising therapeutic effects on hematological malignancies. However, there are problems such as relapse during long-term follow-up and limited effect on solid tumors with this therapy. Exhaustion, which impairs in vivo persistence and killing activity of CAR T cells, is...
Chu, Junfeng Gao, Fengcai Yan, Meimei Zhao, Shuang Yan, Zheng Shi, Bian Liu, Yanyan
Published in
Journal of Translational Medicine
As a promising alternative platform for cellular immunotherapy, natural killer cells (NK) have recently gained attention as an important type of innate immune regulatory cell. NK cells can rapidly kill multiple adjacent cancer cells through non-MHC-restrictive effects. Although tumors may develop multiple resistance mechanisms to endogenous NK cell...
Okamura, Kazumi Nagayama, Satoshi Tate, Tomohiro Chan, Hiu Ting Kiyotani, Kazuma Nakamura, Yusuke
Published in
Journal of Translational Medicine
Background Tumor-draining lymph nodes (TDLNs) are primary sites, where anti-tumor lymphocytes are primed to tumor-specific antigens and play pivotal roles in immune responses against tumors. Although adoptive cell therapy (ACT) using lymphocytes isolated from TDLNs were reported, characterization of immune activity of lymphocytes in TDLNs to tumor ...
